Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mevinolinic acid is the active hydroxy-acid metabolite of lovastatin (originally named Mevinolin), a member of the statin class of drugs. It is produced by hydrolysis of the lactone ring in lovastatin and acts as a highly potent competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in cholesterol biosynthesis. By inhibiting this enzyme, mevinolinic acid reduces endogenous cholesterol production in the liver. The compound was originally isolated from Aspergillus terreus and has been shown to lower plasma cholesterol levels in animal models. Mevinolinic acid itself is not marketed as a drug but represents the pharmacologically active form generated from prodrug statins like lovastatin after administration[1][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mevinolinic acid.